Information Provided By:
Fly News Breaks for September 25, 2019
MNTA
Sep 25, 2019 | 07:06 EDT
H.C. Wainwright analyst Douglas Tsao started Momenta Pharmaceuticals with a Buy rating and $24 price target. The analyst thinks M281, an anti-FcRn antibody, and M254, the company's hypersialylated intravenous immunoglobulin, have the potential to become blockbusters in autoimmune rare diseases.